Histone demethylase JMJD2D emerges as a novel prognostic biomarker and exhibits correlation with immune infiltration in lung adenocarcinoma.

BACKGROUND: Lysine demethylase 4D (KDM4D or JMJD2D) plays a significant role in tumorigenesis, development, and poor clinical outcomes. However, its roles in lung adenocarcinoma (LUAD) remains unclear. This study aimed to identify the role and molecular mechanisms of JMJD2D in LUAD. METHODS: The study investigated the correlation of JMJD2D with tumor development, immune cell infiltration, response to antitumor therapy, tumor mutation burden and prognostic values. RESULTS: JMJD2D had high expression in LUAD. High-JMJD2D expression was associated with poor survival outcomes and the T stage of LUAD patients. Furthermore, high-JMJD2D expression was linked to the decreased immune-related processes, associated with the increased Tregs and CD40 expression. Additionally, high-JMJD2D expression was associated with frequent alterations with higher TMB and resistance to BMS.708,163, Roscovitine, and Pyrimethamine, but sensitivities to ATRA, Bosutinib, and JNK. Inhibitor. VIII. Moreover, the study identified eight JMJD2D-related genes as a prognostic signature and constructed a predictive nomogram based on independent prognostic factors. CONCLUSION: JMJD2D acts as an oncogene in LUAD and is involved in tumorigenesis, development, and poor clinical outcomes. Therefore, JMJD2D may serve as a potential prognostic biomarker in diagnosis and treatment of LUAD. The study emphasizes the importance of the molecular mechanisms of JMJD2D in LUAD.